Strong Financial Performance
Operating revenue for FY2025 was $2.02 billion, up 16% from FY2024, with net profit after tax increasing by 43%.
Hospital Operating Revenue Growth
Hospital operating revenue was $1.28 billion, a growth of 18% compared to FY2024.
Positive Cash Flow and Dividend
Operating cash flow increased by 28%, and a fully imputed final dividend of $0.24 per share was declared, a 2% increase from the previous year.
Gross Margin Improvement
Gross margin improved by 181 basis points to 62.9%, driven by manufacturing and overhead efficiencies.
New Product Launches
Introduction of new products such as the Nova Nasal and Airvo 3, which were well received.